Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Outcomes of First-Line Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and High-Risk Genomic Features with up to 6.5 Years Follow-up: Integrated Analysis of Two Phase 3 Studies (RESONATE-2 and iLLUMINATE)

Jan A. Burger, MD PhD, Tadeusz Robak, MDPhD, Fatih Demirkan, MD, Osnat Bairey, MD, Carol Moreno, MD PhD, David Simpson, MBChB, FRACP, FRCPA, Talha Munir, MBBS, Don A. Stevens, MD, Sandra Dai, PhD MS, Leo W. K. Cheung, PhD, Kevin Kwei, PhD, Indu Lal, MD, Emily Hsu, PhD, Thomas J. Kipps, MD PhD, Alessandra Tedeschi, MD

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-134437

Published: 2020

Journal Articles

Treatment with the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) Demonstrates High Overall Response Rate and Durable Responses in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Updated Results from a Phase 1/2 Trial

Gavin Cull, MB, BS, FRACP, FRCPA, David Simpson, MBChB, FRACP, FRCPA, Stephen Opat, Jan A. Burger, MD PhD, Judith Trotman, MBChB, FRACP, FRCPA, Paula Marlton, MBBS (Hons), FRACP, FRCPA, David Gottlieb, MBBS, MD FRACP, FRCPA, Javier Munoz, MD MS, FACP, John F. Seymour, MBBS, PhD FRACP, Andrew W. Roberts, MBBS, PhD, Ken Wu, PhD, Siminder Atwal, PhD, William Novotny, MD, Jane Huang, MD, Constantine S. Tam, MBBS, MD

Blood (2019) 134 (Supplement_1): 500.

https://doi.org/10.1182/blood-2019-125483

Published: 2019

Journal Articles

Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naive Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with Del(17p): Initial Results from Arm C of the Sequoia (BGB-3111-304) Trial

Blood (2019) 134 (Supplement_1): 499.

https://doi.org/10.1182/blood-2019-125394

Published: 2019

Journal Articles

Fixed Dose Carfilzomib Triplets in Lenalidomide Refractory Myeloma

David Simpson, MBChB, FRACP, FRCPA, Henry Chan, MBChB

Blood (2018) 132 (Supplement 1): 3306.

https://doi.org/10.1182/blood-2018-99-110891

Published: 2018

Journal Articles

Single Centre Experience in Treating Elderly Patients with Acute Myeloid Leukaemia or High Risk Myelodysplastic Syndrome with a Combination of Low Dose Cytarabine, Venetoclax and Fluconazole (VeLDAC-F)

Lauren Child, Henry Chan, MBChB, Ross Alistair Henderson, PhD MBChB, Anna Elinder, MBChB, Eileen Merriman, MBChB, Merit Hanna, MBChB, David Simpson, MBChB, FRACP, FRCPA

Blood (2018) 132 (Supplement 1): 5220.

https://doi.org/10.1182/blood-2018-99-115993

Published: 2018

Journal Articles

Durable Responses in Fit Elderly Patients with Chronic Lymphocytic Leukemia (CLL) in a Randomised, Fludarabine-Based, Immunochemotherapy Dose De-Escalation Study - Long-Term Follow-up By Treatment Arm and Mutational Status

Stephen P. Mulligan, PhD FRACP, FRCPA, MBBS, Devinder Gill, MD MRCP, FRCPath, Gavin Cull, MB, BS, DM, FRACP, FRCPA, Leanne Berkahn, MD, David Simpson, MBChB, FRACP, FRCPA, Philip Campbell, MBBS, FRACP, FRCPA, Rosemary Anne Harrup, MD, Naomi J. Mackinlay, MB BS, FRACP, FRCPA, Constantine S. Tam, MBBS, MD FRACP, FRCPA, Xavier Badoux, MBBS, AB, FRACP, FRCPA, Oliver Giles Best, PhD BSc, Bryone Jean Kuss, PhD BMBS, FRCPA, FRACP

Blood (2018) 132 (Supplement 1): 4432.

https://doi.org/10.1182/blood-2018-99-114064

Published: 2018

Journal Articles

Bing Neel Syndrome: Retrospective Australasian Experience of a Rare Treatable Complication of Waldenström Macroglobulinaemia/ Lymphoplasmacytic Lymphoma

Dipti Talaulikar, PhD FRACP, FRCPA, MBBS, Tara Cochrane, MBBS, John Gibson, Nada Hamad, MBBS, BSc, MSc, Phoebe Joy Ho, MBBS DPhil FRACP FRCPA, Samar Issa, FRACP, Kwok Fiona, Jun Hee Lim, PhD, David Simpson, MBChB, FRACP, FRCPA, Constantine Tam, MD PhD, Jorge J. Castillo, MD

Blood (2018) 132 (Supplement 1): 5325.

https://doi.org/10.1182/blood-2018-99-113969

Published: 2018

Journal Articles

Single-Agent Ibrutinib Versus Chlorambucil-Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results of a Cross-Trial Comparison

Blood (2018) 132 (Supplement 1): 5565.

https://doi.org/10.1182/blood-2018-99-111369

Published: 2018

Journal Articles

Updated Safety and Activity of the Investigational Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Mantle Cell Lymphoma

Constantine S. Tam, MBBS (Hons), MD FRACP, FRCPA, Michael Wang, MD, David Simpson, MBChB, FRACP, FRCPA, Stephen Opat, MBBS (Hons), FRACP, FRCPA, Gavin Cull, MB, BS, DM, FRACP, FRCPA, Javier Munoz, MD, Tycel J. Phillips, MD, Won-Seog Kim, MD PhD, James Hilger, PhD, Jane Huang, MD, William Novotny, MD, Judith Trotman

Blood (2018) 132 (Supplement 1): 1592.

https://doi.org/10.1182/blood-2018-99-117224

Published: 2018

Journal Articles

Ibrutinib for the Treatment of Bing-Neel Syndrome

Gilad Itchaki, Jonas Paludo, MD, Maria Lia Palomba, MD, Marzia Varettoni, MD, Dipti Talaulikar, PhD FRACP, FRCPA, MBBS, Julio C. Chavez, MD, Christian Buske, MD, Alessandra Tedeschi, MD, David Simpson, MBChB, FRACP, FRCPA, Constantine S. Tam, MBBS (Hons), MD FRACP, FRCPA, Samar Issa, FRACP, Stephen M. Ansell, MD PhD, Steven P Treon, MD PhD FRCP, Jorge J. Castillo, MD

Blood (2018) 132 (Supplement 1): 1609.

https://doi.org/10.1182/blood-2018-99-116788

Published: 2018

Journal Articles

High Major Response Rate, Including Very Good Partial Responses (VGPR), in Patients (pts) with Waldenstrom Macroglobulinemia (WM) Treated with the Highly Specific BTK Inhibitor Bgb-3111: Expansion Phase Results from an Ongoing Phase I Study

Constantine S. Tam, MBBS, Judith Trotman, MBChB, Stephen Opat, MD, Paula Marlton, MBBS, Gavin Cull, MBBS DM FRACP FRCPA, David Simpson, MBChB, FRACP, FRCPA, Matthew Ku, MBBS, David Ritchie, MD PhD, Emma Verner, FRACP, FRCPA, MBBS, Sumita Ratnasingam, MBBS, Mary Ann Anderson, MBBS, Peter Wood, MD FRACP, FRCPA, MBBS, Mark Kirschbaum, MD, Lai Wang, PhD, Ling Xue, Jianxin Yang, Eric Hedrick, John F Seymour, Andrew W. Roberts

Blood (2016) 128 (22): 1216.

https://doi.org/10.1182/blood.V128.22.1216.1216

Published: 2016

Journal Articles

Results of the Phase 3 Study of Lenalidomide Versus Placebo As Maintenance Therapy Following Second-Line Treatment for Patients with Chronic Lymphocytic Leukemia (the CONTINUUM Trial)

Robin Foà, MD, Anna Schuh, MD PhD, Andrey Zaritskey, MD, Sergey Semochkin, MD PhD, David Simpson, MBChB, FRACP, FRCPA, Miklos Egyed, Samuel Vokurka, MD PhD, Jeannine Kassis, MDFRCP, Jennie Zhang, PhD, Brendan Purse, BA, MBA, Asher A. Chanan-Khan, MD

Blood (2016) 128 (22): 230.

https://doi.org/10.1182/blood.V128.22.230.230

Published: 2016

Journal Articles

Twice Daily Dosing with the Highly Specific BTK Inhibitor, Bgb-3111, Achieves Complete and Continuous BTK Occupancy in Lymph Nodes, and Is Associated with Durable Responses in Patients (pts) with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Constantine S. Tam, MBBS, Stephen Opat, MD, Gavin Cull, MBBS DM FRACP FRCPA, Judith Trotman, MBChB, David Gottlieb, MBBS MD FRACP FRCPA, David Simpson, MBChB, FRACP, FRCPA, Paula Marlton, MBBS, Mary Ann Anderson, MBBS, Matthew Ku, MBBS, David Ritchie, MD PhD, Sumita Ratnasingam, MBBS, Bradley Augustson, Mark Kirschbaum, MD, Lai Wang, PhD, Ling Xue, Jianxin Yang, Eric Hedrick, John F Seymour, Andrew W. Roberts

Blood (2016) 128 (22): 642.

https://doi.org/10.1182/blood.V128.22.642.642

Published: 2016

Journal Articles

A Randomised Dose De-Escalation Study of Oral Fludarabine, ±Oral Cyclophosphamide and Intravenous Rituximab As First-Line Therapy of Fit Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years: Final Analysis of Response and Toxicity

Stephen P. Mulligan, MBBS (Hons), PhD, FRACP, FRCPA, Devinder Gill, MB, FRCPath, FRACP, FRCPA, Paul Turner, MBBS FRACP FRCPA, William E. P. Renwick, MBBS, FRACP, FRCPA, Maya Latimer, MBBS, FRACP, FRCPA, Naomi Mackinlay, MB BS FRACP FRCPA, Leanne Berkahn, MD, David Simpson, MBChB, FRACP, FRCPA, Philip Campbell, MBBS, FRACP, FRCPA, Cecily J Forsyth, MB BS, FRACP, FRCPA, Gavin Cull, MBBS, DM, FRACP, FRCPA, Rosemary Harrup, MB BS, FRACP, FRCPA, Melanie Sulda, B.Sc, PhD, Giles Best, BSc (Hons), PhD, Mathias Bressel, MSc, Juliana Di Iulio, BAppSc, PhD, Bryone J Kuss, MBBS, PhD FRCPA, FRACP

Blood (2014) 124 (21): 3325.

https://doi.org/10.1182/blood.V124.21.3325.3325

Published: 2014

Journal Articles

Renal Amyloidosis - Tempo of Proteinuria Resolution in Bortezomib Era

Henry Siu Him Chan, MBChB, Janak Rashme De Zoysa, David Simpson, MBChB, FRACP, FRCPA

Blood (2014) 124 (21): 5651.

https://doi.org/10.1182/blood.V124.21.5651.5651

Published: 2014

Journal Articles

Teniposide, Cyclophosphamide, and Prednisone in Myeloma after Bortezomib and Imid Failure Is a Useful Option

Kirsty Ann Louise Marshall, MBChB, Henry Siu Him Chan, MBChB, David Simpson, MBChB, FRACP, FRCPA

Blood (2014) 124 (21): 5767.

https://doi.org/10.1182/blood.V124.21.5767.5767

Published: 2014

Journal Articles

Polynesian Variant Of Idiopathic Multicentric Castleman Disease

Shaun Zhai, MBChB, David Simpson, MBChB, FRACP, FRCPA

Blood (2013) 122 (21): 5127.

https://doi.org/10.1182/blood.V122.21.5127.5127

Published: 2013

Journal Articles

Weekly Subcutaneous Bortezomib Is Well Tolerated and Effective As Initial Therapy Of Symptomatic Myeloma

David Simpson, MBChB, FRACP, FRCPA, Rory McCulloch, MBChB, James Liang, MBChB, Sarah Mant, Naomi Whyler, Liam J. Fernyhough, MB, BS,, BMedSci

Blood (2013) 122 (21): 3229.

https://doi.org/10.1182/blood.V122.21.3229.3229

Published: 2013

Journal Articles

Thalidomide: An Active Agent in AILT Lymphoma

Ross Henderson, David Simpson, MBChB, FRACP, FRCPA, Merit Hanna, MBChB, FRCPA, Sanjeev Chunilal

Blood (2008) 112 (11): 4960.

https://doi.org/10.1182/blood.V112.11.4960.4960

Published: 2008

NARROW

Outcomes of First-Line Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and High-Risk Genomic Features with up to 6.5 Years Follow-up: Integrated Analysis of Two Phase 3 Studies (RESONATE-2 and iLLUMINATE)

Treatment with the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) Demonstrates High Overall Response Rate and Durable Responses in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Updated Results from a Phase 1/2 Trial

Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naive Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with Del(17p): Initial Results from Arm C of the Sequoia (BGB-3111-304) Trial

Fixed Dose Carfilzomib Triplets in Lenalidomide Refractory Myeloma

Single Centre Experience in Treating Elderly Patients with Acute Myeloid Leukaemia or High Risk Myelodysplastic Syndrome with a Combination of Low Dose Cytarabine, Venetoclax and Fluconazole (VeLDAC-F)

Durable Responses in Fit Elderly Patients with Chronic Lymphocytic Leukemia (CLL) in a Randomised, Fludarabine-Based, Immunochemotherapy Dose De-Escalation Study - Long-Term Follow-up By Treatment Arm and Mutational Status

Bing Neel Syndrome: Retrospective Australasian Experience of a Rare Treatable Complication of Waldenström Macroglobulinaemia/ Lymphoplasmacytic Lymphoma

Single-Agent Ibrutinib Versus Chlorambucil-Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results of a Cross-Trial Comparison

Updated Safety and Activity of the Investigational Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Mantle Cell Lymphoma

Ibrutinib for the Treatment of Bing-Neel Syndrome

High Major Response Rate, Including Very Good Partial Responses (VGPR), in Patients (pts) with Waldenstrom Macroglobulinemia (WM) Treated with the Highly Specific BTK Inhibitor Bgb-3111: Expansion Phase Results from an Ongoing Phase I Study

Results of the Phase 3 Study of Lenalidomide Versus Placebo As Maintenance Therapy Following Second-Line Treatment for Patients with Chronic Lymphocytic Leukemia (the CONTINUUM Trial)

Twice Daily Dosing with the Highly Specific BTK Inhibitor, Bgb-3111, Achieves Complete and Continuous BTK Occupancy in Lymph Nodes, and Is Associated with Durable Responses in Patients (pts) with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

A Randomised Dose De-Escalation Study of Oral Fludarabine, ±Oral Cyclophosphamide and Intravenous Rituximab As First-Line Therapy of Fit Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years: Final Analysis of Response and Toxicity

Renal Amyloidosis - Tempo of Proteinuria Resolution in Bortezomib Era

Teniposide, Cyclophosphamide, and Prednisone in Myeloma after Bortezomib and Imid Failure Is a Useful Option

Polynesian Variant Of Idiopathic Multicentric Castleman Disease

Weekly Subcutaneous Bortezomib Is Well Tolerated and Effective As Initial Therapy Of Symptomatic Myeloma

Thalidomide: An Active Agent in AILT Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only